Transgene and Nec Report 100% Three-Year Disease-Free
The primary endpoint objective response rate (ORR) was 90.3% (95% CI, 74.2–98.0%).
The primary endpoint objective response rate (ORR) was 90.3% (95% CI, 74.2–98.0%).
Phase II data supporting a high ORR in unresectable locally advanced or metastatic adenoid cystic carcinoma of the head and neck.
Evidence level: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Related signals
- Spatial Profiling of the Head and Neck Squamous Cell Carcinoma Microenvironment: Reshaping Our Understanding and Therapeutic Opportunities
- Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer
- Review Systemic therapy in the curative treatment of head and neck squamous cell cancer: a systematic review
- Preclinical models in head and neck squamous cell carcinoma
- CAR-Based Cell Therapy in Head and Neck Cancer: A Comprehensive Review on Clinical Applicability